Literature DB >> 30004625

Recombinant activated factor VII in approved indications: Update on safety.

E J Neufeld1, C Négrier2, S Benchikh El Fegoun3, D L Cooper4, A Rojas-Rios5, S Seremetis4.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30004625     DOI： 10.1111/hae.13547

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  2 in total

1.  The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors.

Authors:  Miguel Escobar; Giancarlo Castaman; Santiago Bonanad Boix; Michael Callaghan; Philippe de Moerloose; Jonathan Ducore; Cédric Hermans; Janna Journeycake; Cindy Leissinger; James Luck; Johnny Mahlangu; Wolfgang Miesbach; Ismail Haroon Mitha; Claude Négrier; Doris Quon; Michael Recht; Jean François Schved; Amy D Shapiro; Robert Sidonio; Alok Srivastava; Oleksandra Stasyshyn; Kateryna V Vilchevska; Michael Wang; Guy Young; W Allan Alexander; Ahmad Al-Sabbagh; Daniel Bonzo; Christopher Macie; Thomas A Wilkinson; Craig Kessler
Journal:  Haemophilia       Date:  2021-10-11       Impact factor: 4.263

2.  Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC).

Authors:  Madhvi Rajpurkar; Stacy E Croteau; Lisa Boggio; David L Cooper
Journal:  J Blood Med       Date:  2019-09-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.